Lumpipulse G CA19-9-N

System, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer

Fujirebio Dianostics, Inc.

The following data is part of a premarket notification filed by Fujirebio Dianostics, Inc. with the FDA for Lumpipulse G Ca19-9-n.

Pre-market Notification Details

Device IDK191973
510k NumberK191973
Device Name:Lumpipulse G CA19-9-N
ClassificationSystem, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer
Applicant Fujirebio Dianostics, Inc. 201 Great Valley Parkway Malvern,  PA  19355
ContactKristin Maddaloni
CorrespondentKristin Maddaloni
Fujirebio Dianostics, Inc. 201 Great Valley Parkway Malvern,  PA  19355
Product CodeNIG  
CFR Regulation Number866.6010 [🔎]
DecisionSubstantially Equivalent (SESE)
TypeTraditional
3rd Party ReviewedNo
Combination ProductNo
Date Received2019-07-24
Decision Date2019-10-22
Summary:summary

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.